49 related articles for article (PubMed ID: 3457647)
1. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
[TBL] [Abstract][Full Text] [Related]
2. Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.
Buckley MM; Lamb HM
Drugs Aging; 1997 Jul; 11(1):61-86. PubMed ID: 9237041
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of idarubicin.
Robert J
Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
[TBL] [Abstract][Full Text] [Related]
4. Oral idarubicin--an anthracycline derivative with unique properties.
Goebel M
Ann Hematol; 1993 Jan; 66(1):33-43. PubMed ID: 8431520
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
[TBL] [Abstract][Full Text] [Related]
6. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.
Camaggi CM; Strocchi E; Comparsi R; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1986; 18(1):47-50. PubMed ID: 3463434
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.
Milroy R; Cummings J; Kaye SB; Banham SW
Cancer Chemother Pharmacol; 1987; 20(1):75-7. PubMed ID: 3040287
[TBL] [Abstract][Full Text] [Related]
8. Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.
Cummings J; Milroy R; Banham SW; Kaye SB
Cancer Chemother Pharmacol; 1987; 19(4):296-300. PubMed ID: 3036387
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacology of oral idarubicin.
Stewart DJ; Grewaal D; Green RM; Verma S; Maroun JA; Redmond D; Robillard L; Gupta S
Cancer Chemother Pharmacol; 1991; 27(4):308-14. PubMed ID: 1998987
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
Hollingshead LM; Faulds D
Drugs; 1991 Oct; 42(4):690-719. PubMed ID: 1723369
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Camaggi CM; Strocchi E; Carisi P; Martoni A; Tononi A; Guaraldi M; Strolin-Benedetti M; Efthymiopoulos C; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):307-16. PubMed ID: 1643700
[TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Camaggi CM; Carisi P; Strocchi E; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):303-6. PubMed ID: 1643699
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).
Lu K; Savaraj N; Kavanagh J; Feun LG; Burgess M; Bodey GP; Loo TL
Cancer Chemother Pharmacol; 1986; 17(2):143-8. PubMed ID: 3459594
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
15. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Martoni A; Pacciarini MA; Pannuti F
Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
[TBL] [Abstract][Full Text] [Related]
16. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
18. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Pannuti F; Camaggi CM; Strocchi E; Comparsi R; Angelelli B; Pacciarini MA
Cancer Chemother Pharmacol; 1986; 16(3):295-9. PubMed ID: 3457647
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
